Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles

Advanced Drug Delivery Reviews

Volumn 63, Issue 10-11, 2011, Pages 901-908

  Cai, Shuang ^a   Yang, Qiuhong ^a   Bagby, Taryn R ^a   Forrest, M Laird ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Engineered liposomes; Lymphatic drug delivery; Lymphatic imaging; Nanotechnology; Solid lipid nanoparticles

Indexed keywords

DELIVERY DEVICE; DIAGNOSTIC AGENTS; DRUG MOLECULES; ENGINEERED LIPOSOMES; HEALTHY TISSUES; IMMUNE SYSTEMS; LYMPHATIC DRUG DELIVERY; LYMPHATIC IMAGING; LYMPHATIC SYSTEMS; SOLID CANCER; SOLID LIPID NANOPARTICLES;

BIOCHEMISTRY; DRUG DELIVERY; LIPOSOMES; NANOPARTICLES; PHOSPHOLIPIDS; TUMORS;

DISEASES;

ALPHA TOCOPHEROL DERIVATIVE; ANGIOTENSIN II DERIVATIVE; ANGIOTENSIN II IN 111; ANTINEOPLASTIC AGENT; AVIDIN; CARBOXYFLUORESCEIN; CPG OLIGODEOXYNUCLEOTIDE; DILAUROYLPHOSPHATIDYLCHOLINE; DNA VACCINE; DOXORUBICIN; FC RECEPTOR; HLA DR ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOLIPOSOME; INDINAVIR; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; NANOPARTICLE; PACLITAXEL; PENTETATE INDIUM IN 111; PENTETIC ACID; PLASMID DNA; RECOMBINANT DNA; RUBITECAN; SOLID LIPID NANOPARTICLE; TECHNETIUM 99M; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; AREA UNDER THE CURVE; BREAST CANCER; BREAST METASTASIS; BREAST TUMOR; CANCER GROWTH; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER PREVENTION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DRUG ACCUMULATION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG LYMPH LEVEL; DRUG MEGADOSE; DRUG PENETRATION; DRUG RELEASE; DRUG STABILITY; DRUG TRANSPORT; DRUG UPTAKE; ENCAPSULATION; ENZYMATIC DEGRADATION; FIRST PASS EFFECT; HEAD AND NECK TUMOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROPHILICITY; IMAGING SYSTEM; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; ISOTOPE LABELING; KAPOSI SARCOMA; LIPOSOMAL DELIVERY; LOW DRUG DOSE; LUNG CANCER; LYMPH NODE METASTASIS; LYMPHATIC DRAINAGE; LYMPHATIC SYSTEM; LYMPHOGRAPHY; MELANOMA; MICELLE; MOLECULAR IMAGING; MONOTHERAPY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY; SINGLE DRUG DOSE; STOMACH JUICE; SURVIVAL RATE; THYMOMA; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIPIDS; LIPOSOMES; LYMPHATIC SYSTEM; NANOPARTICLES; NEOPLASMS;

EID: 80052271643     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.05.017     Document Type: Review

References (56)

1. Harrington K.J., Rowlinson-Busza G., Syrigos K.N., Uster P.S., Vile R.G., Stewart J.S. Pegylated liposomes have potential as vehicles for intratumoral and subcutaneous drug delivery. Clin. Cancer Res. 2000, 6:2528-2537.
2. Moghimi S.M., Moghimi M. Enhanced lymph node retention of subcutaneously injected IgG1-PEG2000-liposomes through pentameric IgM antibody-mediated vesicular aggregation. Biochim. Biophys. Acta 2008, 1778:51-55.
3. Moghimi S.M. The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. Biomaterials 2006, 27:136-144.
4. Phillips W.T., Klipper R., Goins B. Novel method of greatly enhanced delivery of liposomes to lymph nodes. J. Pharmacol. Exp. Ther. 2000, 295:309-313.
5. Hashida N., Murakami M., Yoshikawa H., Takada K., Muranishi S. Intestinal absorption of carboxyfluorescein entrapped in liposomes in comparison with its administration with lipid-surfactant mixed micelles. J. Pharmacobiodyn. 1984, 7:195-203.
6. Perrie Y., Obrenovic M., McCarthy D., Gregoriadis G. Liposome (Lipodine)-mediated DNA vaccination by the oral route. J. Liposome Res. 2002, 12:185-197.
7. Latimer P., Menchaca M., Snyder R.M., Yu W., Gilbert B.E., Sanders B.G., Kline K. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases. Exp. Biol. Med. (Maywood) 2009, 234:1244-1252.
8. Rabaca Roque Botelho M.F., Tavares Marques M.A., Freitas Gomes C.M., Marques Ferreira da Silva A., Andrade Figueiredo Bairos V.A., de Matos Santos Rosa M.A., Pena Abrunhosa A., Pedroso de Lima J.J. Nanoradioliposomes molecularly modulated to study the lung deep lymphatic drainage. Rev. Port. Pneumol. 2009, 15:261-293.
9. Frenkel V., Etherington A., Greene M., Quijano J., Xie J., Hunter F., Dromi S., Li K.C. Delivery of liposomal doxorubicin (Doxil) in a breast cancer tumor model: investigation of potential enhancement by pulsed-high intensity focused ultrasound exposure. Acad. Radiol. 2006, 13:469-479.
10. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., Catane R., Kieback D.G., Tomczak P., Ackland S.P., Orlandi F., Mellars L., Alland L., Tendler C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 2004, 15:440-449.
11. Tejada-Berges T., Granai C.O., Gordinier M., Gajewski W. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert. Rev. Anticancer. Ther. 2002, 2:143-150.
12. Prescott L.M. Doxil offers hope to KS sufferers. J. Int. Assoc. Physicians AIDS Care 1995, 1:43-44.
13. Soundararajan A., Bao A., Phillips W.T., Perez R.r., Goins B.A. [(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl. Med. Biol. 2009, 36:515-524.
14. Ling R., Li Y., Yao Q., Chen T., Zhu D., Jun Y., Chen J. Lymphatic chemotherapy induces apoptosis in lymph node metastases in a rabbit breast carcinoma model. J. Drug Target. 2005, 13:137-142.
15. Trubetskoy V.S., Whiteman K.R., Torchilin V.P., Wolf G.L. Massage-induced release of subcutaneously injected liposome-encapsulated drugs to the blood. J. Control Release 1998, 50:13-19.
16. Ling S.S., Magosso E., Khan N.A., Yuen K.H., Barker S.A. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev. Ind. Pharm. 2006, 32:335.
17. Kraft S.L., Dailey D., Kovach M., Stasiak K.L., Bennett J., McFarland C.T., McMurray D.N., Izzo A.A., Orme I.M., Basaraba R.J. Magnetic resonance imaging of pulmonary lesions in guinea pigs infected with Mycobacterium tuberculosis. Infect. Immun. 2004, 72:5963-5971.
18. Lawson K.A., Anderson K., Snyder R.M., Simmons-Menchaca M., Atkinson J., Sun L.Z., Bandyopadhyay A., Knight V., Gilbert B.E., Sanders B.G., Kline K. Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis. Cancer Chemother. Pharmacol. 2004, 54:421-431.
19. Cui Z., Han S.J., Huang L. Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor. Pharm. Res. 2004, 21:1018-1025.
20. Desormeaux A., Bergeron M.G. Lymphoid tissue targeting of anti-HIV drugs using liposomes. Methods Enzymol. 2005, 391:330-351.
21. Bestman-Smith J., Gourde P., Desormeaux A., Tremblay M.J., Bergeron M.G. Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1. Biochim. Biophys. Acta 2000, 1468:161-174.
22. Mui B., Raney S.G., Semple S.C., Hope M.J. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J. Pharmacol. Exp. Ther. 2001, 298:1185-1192.
23. de Jong S., Chikh G., Sekirov L., Raney S., Semple S., Klimuk S., Yuan N., Hope M., Cullis P., Tam Y. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol. Immunother. 2007, 56:1251-1264.
24. Kojima N., Biao L., Nakayama T., Ishii M., Ikehara Y., Tsujimura K. Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity. J. Control. Release 2008, 129:26-32.
25. Butts C., Murray N., Maksymiuk A., Goss G., Marshall E., Soulières D., Cormier Y., Ellis P., Price A., Sawhney R., Davis M., Mansi J., Smith C., Vergidis D., Ellis P., MacNeil M., Palmer M. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 2005, 23:6674-6681.
26. Neidhart J., Allen K.O., Barlow D.L., Carpenter M., Shaw D., Triozzi P.L., Conry R.M. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Vaccine 2004, 22:773-780.
27. Phillips W.T., Goins B. Assessment of liposome delivery using scintigraphic imaging. J. Liposome Res. 2002, 12:71-80.
28. Phillips W.T., Andrews T., Liu H., Klipper R., Landry A.J., Blumhardt R., Goins B. Evaluation of [(99m)Tc] liposomes as lymphoscintigraphic agents: comparison with [(99m)Tc] sulfur colloid and [(99m)Tc] human serum albumin. Nucl. Med. Biol. 2001, 28:435-444.
29. Bagaria S.P., Faries M.B., Morton D.L. Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute. J. Surg. Oncol. 2010, 101:669-676.
30. Yamamoto T., Tamura M., Hamauzu T., Nakayama A., Kawasugi K., Kamakura M., Kinoshita T., Kuyama Y., Yamanaka M., Wang L.M., Sanaka M., Mineshita S. Intestinal Behçet's disease associated with non-Hodgkin's lymphoma. J. Gastroenterol. 1997, 32:241-245.
31. Luongo J.A., Scalcione L.R., Katz D.S., Yung E.Y. Progression of clinically stable lymphedema on lymphoscintigraphy. Clin. Nucl. Med. 2009, 34:585-588.
32. Bourgeois P., Dargent J.L., Larsimont D., Munck D., Sales F., Boels M., De Valck C. Lymphoscintigraphy in angiomyomatous hamartomas and primary lower limb lymphedema. Clin. Nucl. Med. 2009, 34:405-409.
33. Plut E.M., Hinkle G.H., Guo W., Lee R.J. Kit formulation for the preparation of radioactive blue liposomes for sentinel node lymphoscintigraphy. J. Pharm. Sci. 2002, 91:1717-1732.
34. Fujimoto Y., Okuhata Y., Tyngi S., Namba Y., Oku N. Magnetic resonance lymphography of profundus lymph nodes with liposomal gadolinium-diethylenetriamine pentaacetic acid. Biol. Pharm. Bull. 2000, 23:97-100.
35. Misselwitz B., Sachse A. Interstitial MR lymphography using Gd-carrying liposomes. Acta Radiol. Suppl. 1997, 412:51-55.
36. Trubetskoy V.S., Cannillo J.A., Milshtein A., Wolf G.L., Torchilin V.P. Controlled delivery of Gd-containing liposomes to lymph nodes: surface modification may enhance MRI contrast properties. Magn. Reson. Imaging 1995, 13:31-37.
37. Zavaleta C.L., Phillips W.T., Soundararajan A., Goins B.A. Use of avidin/biotin-liposome system for enhanced peritoneal drug delivery in an ovarian cancer model. Int. J. Pharm. 2007, 337:316-328.
38. Medina L.A., Calixto S.M., Klipper R., Phillips W.T., Goins B. Avidin/biotin-liposome system injected in the pleural space for drug delivery to mediastinal lymph nodes. J. Pharm. Sci. 2004, 93:2595-2608.
39. Medina L.A., Calixto S.M., Klipper R., Li Y., Phillips W.T., Goins B. Mediastinal node and diaphragmatic targeting after intracavitary injection of avidin/99mTc-blue-biotin-liposome system. J. Pharm. Sci. 2006, 95:207-224.
40. Müller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
41. Mehnert W., Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47:165-196.
42. Wong H.L., Bendayan R., Rauth A.M., Li Y., Wu X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 2007, 59:491-504.
43. Harivardhan Reddy L., Sharma R.K., Chuttani K., Mishra A.K., Murthy R.S. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J. Control. Release 2005, 105:185-198.
44. Paliwal R., Rai S., Vaidya B., Khatri K., Goyal A.K., Mishra N., Mehta A., Vyas S.P. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine 2009, 5:184-191.
45. Zara G.P., Bargoni A., Cavalli R., Fundarò A., Vighetto D., Gasco M.R. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J. Pharm. Sci. 2002, 91:1324-1333.
46. Jain R.K. Barriers to drug delivery in solid tumors. Sci. Am. 1994, 271:58-65.
47. Bargoni A., Cavalli R., Caputo O., Fundarò A., Gasco M.R., Zara G.P. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm. Res. 1998, 15:745-750.
48. Cavalli R., Zara G.P., Caputo O., Bargoni A., Fundarò A., Gasco M.R. Transmucosal transport of tobramycin incorporated in SLN after duodenal administration to rats. Part I-a pharmacokinetic study. Pharmacol. Res. 2000, 42:541-545.
49. Cavalli R., Bargoni A., Podio V., Muntoni E., Zara G.P., Gasco M.R. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J. Pharm. Sci. 2003, 92:1085-1094.
50. Videira M.A., Botelho M.F., Santos A.C., Gouveia L.F., de Lima J.J., Almeida A.J. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J. Drug Target. 2002, 10:607-613.
51. Elliott J.A., Osterlind K., Hirsch F.R., Hansen H.H. Metastatic patterns in small-cell lung cancer: correlation of autopsy findings with clinical parameters in 537 patients. J. Clin. Oncol. 1987, 5:246-254.
52. Stenbygaard L.E., Sørensen J.B., Larsen H., Dombernowsky P. Metastatic pattern in non-resectable non-small cell lung cancer. Acta Oncol. 1999, 38:993-998.
53. Hawley A.E., Davis S.S., Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Adv Drug Deliv. Rev. 1995, 17:129-148.
54. Charman W.N., Stella V.J. Lymphatic Transport of Drugs 1992, CRC Press.
55. Oussoren C., Zuidema J., Crommelin D.J., Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection.: II. Influence of liposomal size, lipid composition and lipid dose. Biochim. Biophys. Acta 1997, 1328:261-272.
56. Sanjula B., Shah F.M., Javed A., Alka A. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J. Drug Target. 2009, 17:249-256.